Potential protein-binding displacement interactions with perampanel: An in vitro analysis

Area of Science:

• Pharmacology
• Drug Metabolism and Interactions

Background:

• Plasma protein binding significantly influences drug distribution and active concentrations.
• Drug-drug interactions can occur due to protein-binding displacement, affecting therapeutic outcomes.
• Perampanel is an anti-seizure drug with extensive plasma protein binding (>95%) and a long elimination half-life (~100 hours).

Purpose of the Study:

• To investigate the potential for perampanel to displace highly protein-bound anti-seizure drugs (phenytoin, valproate).
• To assess the potential for warfarin, a highly protein-bound drug, to displace perampanel.
• To evaluate the risk of drug interactions arising from protein-binding displacement involving perampanel.

Main Methods:

• Equilibrium dialysis was used to assess the protein binding of perampanel, phenytoin, valproate, and warfarin.
• Plasma samples were dialyzed against phosphate-buffered saline for 24 hours.
• Phenytoin, valproate, and warfarin were also dialyzed in the presence of perampanel to assess displacement effects.

Main Results:

• Perampanel did not displace phenytoin or valproate from plasma protein binding at clinically relevant concentrations.
• Warfarin did not displace perampanel from plasma protein binding.
• These findings suggest minimal risk of altered unbound drug concentrations due to protein-binding displacement.

Conclusions:

• Perampanel exhibits a low potential for drug interactions mediated by protein-binding displacement.
• Clinicians can be reassured regarding the potential for perampanel to alter the unbound concentrations of other highly protein-bound medications.
• This study provides empirical data to mitigate concerns about drug interactions with perampanel.